E
Pharmagreen Biotech Inc.
PHBI
$0.0011
$0.000.00%
E
Sell
3/14/2023Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D on 03/14/2023.
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/16/2023Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 2/16/2023 due to a substantial increase in the growth index and total return index. Operating cash flow increased 78.87% from -$92.3 to -$19.5, and earnings per share increased from -$0.0003 to -$0.0001.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 2/16/2023 due to a substantial increase in the growth index and total return index. Operating cash flow increased 78.87% from -$92.3 to -$19.5, and earnings per share increased from -$0.0003 to -$0.0001.
D
Sell
2/3/2023Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D- from E+ on 2/3/2023 due to an increase in the total return index.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D- from E+ on 2/3/2023 due to an increase in the total return index.
E
Sell
1/19/2023Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D- on 1/19/2023 due to a substantial decline in the valuation index and growth index. Earnings per share declined from $0.0004 to -$0.0003.
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D- on 1/19/2023 due to a substantial decline in the valuation index and growth index. Earnings per share declined from $0.0004 to -$0.0003.
D
Sell
1/9/2023Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 1/9/2023 due to a decline in the volatility index and total return index.
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 1/9/2023 due to a decline in the volatility index and total return index.
D
Sell
12/23/2022Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 12/23/2022 due to an increase in the volatility index and total return index.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 12/23/2022 due to an increase in the volatility index and total return index.
D
Sell
12/8/2022Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 12/8/2022 due to a decline in the volatility index.
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 12/8/2022 due to a decline in the volatility index.
D
Sell
11/17/2022Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 11/17/2022 due to an increase in the volatility index and total return index.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 11/17/2022 due to an increase in the volatility index and total return index.
D
Sell
11/2/2022Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 11/2/2022 due to a decline in the volatility index and total return index.
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 11/2/2022 due to a decline in the volatility index and total return index.
D
Sell
8/18/2022Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 8/18/2022 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.0026 to $0.0004, and EBIT increased 50.51% from -$462.5 to -$228.9.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 8/18/2022 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.0026 to $0.0004, and EBIT increased 50.51% from -$462.5 to -$228.9.
D
Sell
5/17/2022Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 5/17/2022 due to a decline in the growth index, solvency index and valuation index. EBIT declined 127.72% from -$203.1 to -$462.5, the quick ratio declined from 0.01 to 0, and debt to equity increased from -0.18 to -0.12.
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 5/17/2022 due to a decline in the growth index, solvency index and valuation index. EBIT declined 127.72% from -$203.1 to -$462.5, the quick ratio declined from 0.01 to 0, and debt to equity increased from -0.18 to -0.12.
D
Sell
5/16/2022Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from E+ on 05/16/2022.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D on 05/13/2022.
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D on 05/13/2022.
D
Sell
5/4/2022Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from E+ on 05/04/2022.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/21/2022Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
D
Sell
2/24/2022Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 2/24/2022 due to a substantial increase in the growth index and volatility index. Earnings per share increased from -$0.0023 to $0, and EBIT increased 23.3% from -$264.8 to -$203.1.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 2/24/2022 due to a substantial increase in the growth index and volatility index. Earnings per share increased from -$0.0023 to $0, and EBIT increased 23.3% from -$264.8 to -$203.1.
D
Sell
1/18/2022Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D- from E+ on 1/18/2022 due to an increase in the total return index.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D- from E+ on 1/18/2022 due to an increase in the total return index.
E
Sell
1/3/2022Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D- on 1/3/2022 due to a large decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.0004 to -$0.0023, operating cash flow declined 19.91% from -$45.7 to -$54.8, and EBIT declined 12.49% from -$235.4 to -$264.8.
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D- on 1/3/2022 due to a large decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.0004 to -$0.0023, operating cash flow declined 19.91% from -$45.7 to -$54.8, and EBIT declined 12.49% from -$235.4 to -$264.8.
D
Sell
12/30/2021Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 12/30/2021 due to a decline in the volatility index and total return index.
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 12/30/2021 due to a decline in the volatility index and total return index.
D
Sell
12/13/2021Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 12/13/2021 due to an increase in the volatility index.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 12/13/2021 due to an increase in the volatility index.
D
Sell
11/26/2021Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 11/26/2021 due to a decline in the total return index and volatility index.
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 11/26/2021 due to a decline in the total return index and volatility index.
D
Sell
11/3/2021Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 11/3/2021 due to a noticeable increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.0102 to -$0.0004, operating cash flow increased 54.84% from -$101.2 to -$45.7, and the quick ratio increased from 0.01 to 0.01.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 11/3/2021 due to a noticeable increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.0102 to -$0.0004, operating cash flow increased 54.84% from -$101.2 to -$45.7, and the quick ratio increased from 0.01 to 0.01.
D
Sell
7/21/2021Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D- from E+ on 7/21/2021 due to an increase in the volatility index and valuation index.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D- from E+ on 7/21/2021 due to an increase in the volatility index and valuation index.
E
Sell
7/6/2021Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D- on 7/6/2021 due to a decline in the volatility index.
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D- on 7/6/2021 due to a decline in the volatility index.
D
Sell
6/16/2021Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D- from E+ on 6/16/2021 due to an increase in the volatility index and total return index.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D- from E+ on 6/16/2021 due to an increase in the volatility index and total return index.
E
Sell
5/28/2021Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D- on 5/28/2021 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 2,200% from -$4.4 to -$101.2, earnings per share declined from -$0.0027 to -$0.0102, and the quick ratio declined from 0.01 to 0.01.
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D- on 5/28/2021 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 2,200% from -$4.4 to -$101.2, earnings per share declined from -$0.0027 to -$0.0102, and the quick ratio declined from 0.01 to 0.01.
D
Sell
5/25/2021Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D- from E+ on 5/25/2021 due to an increase in the volatility index and total return index.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D- from E+ on 5/25/2021 due to an increase in the volatility index and total return index.
E
Sell
2/23/2021Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D- on 2/23/2021 due to a decline in the valuation index and volatility index.
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D- on 2/23/2021 due to a decline in the valuation index and volatility index.
D
Sell
2/5/2021Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D- from E+ on 2/5/2021 due to an increase in the volatility index.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D- from E+ on 2/5/2021 due to an increase in the volatility index.
E
Sell
1/8/2021Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D- on 1/8/2021 due to a decline in the growth index, volatility index and solvency index. The quick ratio declined from 0.01 to 0, and EBIT declined 33.5% from -$102.7 to -$137.1.
Pharmagreen Biotech Inc. (PHBI) was downgraded to E+ from D- on 1/8/2021 due to a decline in the growth index, volatility index and solvency index. The quick ratio declined from 0.01 to 0, and EBIT declined 33.5% from -$102.7 to -$137.1.
D
Sell
8/21/2020Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 8/21/2020 due to a noticeable decline in the growth index and solvency index. The quick ratio declined from 0.02 to 0.01, and debt to equity increased from -0.18 to -0.11.
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 8/21/2020 due to a noticeable decline in the growth index and solvency index. The quick ratio declined from 0.02 to 0.01, and debt to equity increased from -0.18 to -0.11.
D
Sell
7/6/2020Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 7/6/2020 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.0027 to $0, and EBIT increased 6.23% from -$126.9 to -$119.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 7/6/2020 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.0027 to $0, and EBIT increased 6.23% from -$126.9 to -$119.
D
Sell
5/1/2020Downgrade
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, solvency index and growth index. The quick ratio declined from 0.05 to 0.02, EBIT declined 30.15% from -$97.5 to -$126.9, and total capital declined 14.16% from -$757.8 to -$865.1.
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, solvency index and growth index. The quick ratio declined from 0.05 to 0.02, EBIT declined 30.15% from -$97.5 to -$126.9, and total capital declined 14.16% from -$757.8 to -$865.1.
D
Sell
7/1/2019Upgraded
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 07/01/2019.
Pharmagreen Biotech Inc. (PHBI) was upgraded to D from D- on 07/01/2019.
D
Sell
6/7/2019None
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from U on 06/07/2019.
Pharmagreen Biotech Inc. (PHBI) was downgraded to D- from U on 06/07/2019.
OTC PK
03/07/2025 3:20PM Eastern
Quotes delayed
